CONFERENCE

December 3, 2019

QSP model of BTK inhibitors developed by InSysBio in collaboration with BeiGene will be presented as a poster by Srikumar Sahasranaman from Beigene at 61st American Society of Hematology (ASH) Annual Meeting & Exposition. The model describes marketed BTK inhibitors (ibrutinib and acalabrutinib) and zanubrutinib, a BTK inhibitor which recently received accelerated approval from the FDA as a treatment for mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy.

September 18, 2019

InSysBio announces their participation at Tenth American Conference on Pharmacometrics (ACoP10) to be held October 20th to 23rd, 2019, at the Rosen Shingle Creek Hotel in Orlando, FL.

March 26, 2019

InSysBio announces their participation at 15th Essential Protein Engineering Summit being held on April 8-12 in Boston, MA.

February 28, 2019

20-22 February 2019 InSysBio company held the 12th Annual Internal Scientific Meeting. Results of the last year and plans for the ongoing year were discussed.

November 6, 2018

InSysBio presents the video of Tatiana Karelina’s talk in framework of session “From translational PKPD models to quantitative system pharmacology in neurodegeneration drug development” at the 9th American Conference on Pharmacometrics (ACoP9):